SPRAVATO® is the first and only approved antidepressant medication shown to begin improving depressive symptoms with the first dose in this challenging to treat patient population
People living with major depression need more options to meet their most critical needs. SPRAVATO® in conjunction with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
SPRAVATO can now help patients with challenging to treat depression find significant and swift relief from debilitating depressive symptoms, offering those living with this serious mental health condition the possibility of a better future. SPRAVATO® (esketamine) has a novel mechanism of action, meaning it works differently than currently available therapies for major depressive disorder (MDD).
Once SPRAVATO® is determined as an appropriate treatment option, in accordance with the REMS, clients will be treated at MindSet Healthcare to administer the medicine and address their needs. The appropriate clients are evaluated and the full course of treatment is delivered in a safe, appropriate and controlled manner for clients to receive the maximum treatment benefit.